NYSE · STVN
Healthcare · Medical - Instruments & Supplies
$14.10
Down-$5.64 (-28.57%)
Updated Nov 4, 2026, 8:42 AM
SID Score
4.6/10
Composite research score
Smart Money
56/100
Neutral
Price performance · STVN
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
STVN closed at $14.10 after 21 trading sessions, down 29.00% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $15.94 | $15.94 | $13.03 | $14.10 | 4.79M |
| Nov 2, 2026 | $19.62 | $20.26 | $19.47 | $19.74 | 772.34K |
| Oct 30, 2026 | $20.51 | $20.80 | $19.03 | $19.38 | 557.66K |
| Oct 29, 2026 | $19.60 | $20.31 | $19.60 | $20.24 | 405.42K |
| Oct 28, 2026 | $19.71 | $19.88 | $19.31 | $19.43 | 277.6K |
| Oct 27, 2026 | $19.85 | $19.88 | $19.28 | $19.64 | 250.53K |
| Oct 26, 2026 | $19.47 | $19.88 | $18.9424 | $19.88 | 182.97K |
| Oct 23, 2026 | $19.46 | $19.765 | $19.24 | $19.49 | 403.47K |
| Oct 22, 2026 | $18.88 | $19.90 | $18.83 | $19.50 | 961.52K |
| Oct 21, 2026 | $18.82 | $19.175 | $18.66 | $18.82 | 408.19K |
| Oct 20, 2026 | $18.88 | $19.07 | $18.76 | $19.01 | 261.86K |
| Oct 19, 2026 | $18.89 | $19.07 | $18.66 | $19.02 | 560.38K |
| Oct 16, 2026 | $19.27 | $19.27 | $18.51 | $18.90 | 277.78K |
| Oct 15, 2026 | $19.30 | $19.56 | $19.15 | $19.25 | 428.51K |
| Oct 14, 2026 | $19.11 | $19.54 | $19.01 | $19.31 | 360.57K |
| Oct 13, 2026 | $19.20 | $19.478 | $18.82 | $19.26 | 398.48K |
| Oct 12, 2026 | $19.755 | $19.755 | $19.10 | $19.24 | 301.08K |
| Oct 9, 2026 | $19.22 | $19.82 | $19.22 | $19.40 | 267.1K |
| Oct 8, 2026 | $19.44 | $19.55 | $19.00 | $19.21 | 233.1K |
| Oct 7, 2026 | $19.61 | $19.86 | $19.18 | $19.44 | 285.69K |
| Oct 6, 2026 | $20.21 | $20.9099 | $19.64 | $19.86 | 236.05K |
The latest Smart Investors Daily articles mentioning STVN.
Company
Market Activity
Research & News
STVN research
Company profile and research snapshot.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | UBS | Neutral | — |
| Jun 16, 2026 | TD Cowen | Buy | — |
| Mar 6, 2026 | Morgan Stanley | Equal-Weight | — |
| Mar 5, 2026 | Citigroup | Buy | — |
| Mar 5, 2026 | Keybanc | Overweight | — |
No generated briefing is available yet.
Yahoo · Oct 28, 2026
Conestoga Capital Advisors, an asset management company, released its third-quarter 2026 investor letter. The letter can be downloaded here. In 2026, Small Caps initially outperformed but faced challenges in the third quarter, marked by the Russell 2000 Growth Index’s -9.4% decline versus the S&P 500’s +2.3% rise. Factors such as rising Treasury yields and higher oil […]
Yahoo · Oct 27, 2026
CRYSTAL LAKE, Ill., October 27, 2026--Aptar Pharma and Stevanato Group Collaborate to Help Accelerate Pre-Filled Syringe System Selection
Yahoo · Oct 27, 2026
PIOMBINO DESE, Italy, October 27, 2026--Stevanato Group S.p.A. (NYSE: STVN) (the "Company"), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced a collaboration with Aptar Pharma to provide system-level data supporting earlier evaluation of pre-filled syringe configurations for biotech and pharmaceutical companies, with a focus on sensitive biologics and other injectable therapi
Yahoo · Oct 20, 2026
PIOMBINO DESE, Italy, October 20, 2026--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the third quarter of 2026 on Tuesday, November 3, 2026, at 6:30 a.m. (EDT).
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning STVN.
